Anastrozole for Breast Cancer

Phase-Based Progress Estimates
1
Effectiveness
2
Safety
Breast Cancer+21 MoreAnastrozole - Drug
Eligibility
18+
Female
What conditions do you have?
Select

Study Summary

This trial is testing anastrozole and letrozole to see if they can help treat stage I-III breast cancer patients and prevent cancer from recurring.

Eligible Conditions
  • Breast Cancer
  • Stage IIA Breast Cancer
  • Stage III Breast Cancer
  • Stage IA Breast Cancer
  • Stage IIIB Breast Cancer
  • Stage IB Breast Cancer
  • Stage IIB Breast Cancer
  • Stage II Breast Cancer
  • Stage 1 Breast Cancer
  • Stage IIIA Breast Cancer
  • Stage 2 Breast Cancer

Treatment Effectiveness

Effectiveness Progress

1 of 3

Similar Trials

Study Objectives

2 Primary · 1 Secondary · Reporting Duration: Up to 10 weeks

After treatment of anastrozole 10 mg once daily and letrozole
Distribution of estrone (E1) and estradiol (E2) concentrations
Up to 10 weeks
Estrogen suppression rate
Incidence of adverse events

Trial Safety

Safety Progress

2 of 3
This is further along than 68% of similar trials

Similar Trials

Side Effects for

Anastrozole
10%Fracture
8%Acne
5%Scoliosis
3%Hair loss
3%Sacroiliitis
3%Neuro event
This histogram enumerates side effects from a completed 2018 Phase 4 trial (NCT02137538) in the Anastrozole ARM group. Side effects include: Fracture with 10%, Acne with 8%, Scoliosis with 5%, Hair loss with 3%, Sacroiliitis with 3%.

Trial Design

1 Treatment Group

Treatment (anastrozole, letrozole)
1 of 1

Experimental Treatment

29 Total Participants · 1 Treatment Group

Primary Treatment: Anastrozole · No Placebo Group · Phase 2

Treatment (anastrozole, letrozole)Experimental Group · 2 Interventions: Anastrozole, Letrozole · Intervention Types: Drug, Drug
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Anastrozole
FDA approved
Letrozole
FDA approved

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: up to 10 weeks

Who is running the clinical trial?

Mayo ClinicLead Sponsor
2,922 Previous Clinical Trials
3,517,124 Total Patients Enrolled
84 Trials studying Breast Cancer
17,027 Patients Enrolled for Breast Cancer
National Cancer Institute (NCI)NIH
13,084 Previous Clinical Trials
41,141,617 Total Patients Enrolled
926 Trials studying Breast Cancer
1,536,366 Patients Enrolled for Breast Cancer
Tufia C HaddadPrincipal InvestigatorMayo Clinic
2 Previous Clinical Trials
144 Total Patients Enrolled

Eligibility Criteria

Age 18+ · Female Participants · 10 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
You have a stage I-III breast cancer.
You have ER positive disease according to ASCO/CAP guidelines as ER > 1% positive nuclear staining.
Treatment with chemotherapy, if needed.